P. Richard Harrigan

The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.

Extreme responses to climate change in Antarctic lakes.

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.

对生存的 CD4 + 细胞计数时启动高活性抗逆转录病毒治疗的艾滋病毒感染成年人改善药物依从性的影响是 0.200 为 0.350 x 10(9) 单元格/l。

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.

The impact of adherence on CD4 cell count responses among HIV-infected patients.

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.

Are untimed antiretroviral drug levels useful predictors of adherence behavior?

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

2004: which HIV-1 drug resistance mutations are common in clinical practice?

Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.

Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence.

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?

Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure.

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

HIV-1 genetic diversity in antenatal cohort, Canada.

Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.

Utilization of a liver allograft from a hepatitis B surface antigen positive donor.

The direct costs of HIV/AIDS care.

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?

HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.

The impact of human genetic variation on HIV disease in the era of HAART.

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model.

Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage.

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.

Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

HIV-1 drug resistance surveillance using dried whole blood spots.

Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.

A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.

Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.

Predicting HIV coreceptor usage on the basis of genetic and clinical covariates.

Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.

CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals.

Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.

Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.

Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection.

Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.

HIV coreceptor phenotyping in the clinical setting.

Bayesian network analyses of resistance pathways against efavirenz and nevirapine.

The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.

Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.

Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag.

HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals.

Adaptation of HIV-1 to human leukocyte antigen class I.

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1.

Epidemiology of treatment failure: a focus on recent trends.

Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.

Connection domain mutations in treatment-experienced patients in the OPTIMA trial.

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

HIV drug resistance over the long haul.

Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.

HIV antiviral drug resistance: patient comprehension.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Epidemiology of antiretroviral multiclass resistance.

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.

Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection.

Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.

Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1.

Genotypic tropism testing: evidence-based or leap of faith?

The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approach.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.

Viral load testing in a resource-limited setting: quality control is critical.

Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.

Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to highly active antiretroviral therapy during pregnancy.